Cell BioEngines, Inc., a clinical-stage biotechnology company focused on delivering stem cell and immune cell therapies to address blood and solid cancers, entered into an agreement with Miltenyi to develop and manufacture its expanded hematopoietic stem cell transplantation (HSCT) product for clinical use in hematology-oncology. Cell BioEngines’ stem cell expansion technology provides an ‘off-the-shelf’ treatment for blood cancer patients who need a bone marrow transplant. It uses a small mo...